Program
fianlimab
Also written as “Fianlimab”, “Fianlimab+cemiplimab” and “FDC fianlimab+cemiplimab”.
Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Ependymoma · Neoplasms, led by Regeneron Pharmaceuticals.
Furthest: phase 3, since Apr 6, 202210 company-led studies, 9 open or runningNext primary completion: Jan 15, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 109 open or running | phase 3since Apr 6, 2022 | Nov 18, 2016 | Jan 15, 2027phase 3 · NCT05608291 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 18, 2016First study: phase 1 study in NeoplasmsFirst studyNCT03005782 · 333 enrolled · United States, Australia, Ireland and more
- Apr 6, 2022Phase 3 study in MelanomaNCT05352672 · 1,546 enrolled · United States, Argentina, Australia and more
- Oct 14, 2022Phase 3 study in MelanomaNCT05608291 · 1,564 enrolled · United States, Argentina, Australia and more
- Mar 14, 20232 phase 3 studiesNCT05785767, NCT05800015
- Nov 29, 2023Phase 2 study in Resectable Non-small Cell Lung CancerNCT06161441 · 195 enrolled · United States, Australia, Chile and more
- Jan 30, 2024Phase 3 study in MelanomaNCT06246916 · 560 planned · United States, Canada
- Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698 · 120 planned · United States, Australia, France and more
- Feb 24, 2025Phase 2 study in MelanomaNCT06848088 · 28 enrolled · United States, Ireland
- Apr 28, 2026Phase 2 study in GliomaNCT07567469 · 120 planned
- Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088
- Nov 10, 2026Primary completion moved from 2026-07-27 to 2027-01-15Date moved laterphase 3 · +6 months · NCT05608291
Ahead
- Jan 15, 2027Primary completion: phase 3 study in MelanomaNCT05608291
- Mar 22, 2027Primary completion: phase 3 study in MelanomaNCT06246916
- Sep 28, 2027Primary completion: phase 3 study in Advanced Non-Small Cell Lung CancerNCT05785767
- Jun 4, 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698
TargetBeta
LAG3 →read by rule
“A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule
Other programs on LAG3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| relatlimabrule | Bristol-Myers Squibb | phase 4 | 19 |
| Anti-PD-1/LAG-3 Bispecific Antibody AK129rule | Akeso | phase 2 | 4 |
| TQB2252 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07567469Glioma | 2 | Not yet recruiting | Aug 27, 2032 | 120 |
| NCT06848088Melanoma · United States, Ireland | 2 | Active, not recruiting | Oct 9, 2030 | 28 |
| NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more | 2 | Recruiting | Jun 4, 2028 | 120 |
| NCT06246916Melanoma · United States, Canada | 3 | Recruiting | Mar 22, 2027 | 560 |
| NCT06161441Resectable Non-small Cell Lung Cancer · United States, Australia, Chile and more | 2 | Active, not recruiting | Aug 24, 2026 | 195 |
| NCT05800015Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 3 | Active, not recruiting | Jan 16, 2030 | 160 |
| NCT05785767Advanced Non-Small Cell Lung Cancer · United States, Australia, Canada and more | 3 | Active, not recruiting | Sep 28, 2027 | 149 |
| NCT05608291Melanoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Jan 15, 2027 | 1,564 |
| NCT05352672Melanoma · United States, Argentina, Australia and more | 3 | Active, not recruiting | Mar 12, 2026 | 1,546 |
| NCT03005782Neoplasms · United States, Australia, Ireland and more | 1 | Completed | Apr 2, 2024 | 333 |
How it is read
Names in the registry
- “Fianlimab”, 3 entries
- “fianlimab”, 3 entries
- “Fianlimab+cemiplimab”, 1 entry
- “FDC fianlimab+cemiplimab”, 1 entry
- “Cemiplimab+Fianlimab Fixed Dose Combination (FDC)”, 1 entry
Conditions, from the studies’ own filings
- Melanoma, 4 studies
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Ependymoma, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.